Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

Also called NCT00987415

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 253 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT00987415
Other papers using this trial's data
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study Circulation, 2015-05-19 DOI, PubMed 25986447, PMC4438785 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00987415. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2014-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Acronym
EXACT-HF
Condition
Heart Failure
Condition
Elevated Serum Uric Acid
Intervention (Drug)
allopurinol
Intervention (Drug)
sugar pill
Lead sponsor
Duke University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct00987415
Content hash
9786d12308958d751e4c41bdf5583a41349d1b01023266643b8528f7fa642b19